B
Bull
Bull · 25%CLGN
$10.06
Szenariopreis
$0.358
+0.084 (+23.58%)Zum Schluss
Loading chart…
- High
- 0.413
- Open
- 0.289
- VWAP
- 0.34
- Vol
- 8.98M
- Mkt Cap
- 57.27M
- Low
- 0.264
- Amount
- 3.10M
- EV/EBITDA, TTM
- -0.02
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
AI analysis of Collplant Biotechnologies Ltd (CLGN)
holdCollplant Biotechnologies Ltd is not a strong buy at the moment. The current price is $0.358, which is significantly below the $1 compliance threshold set by Nasdaq, raising concerns about its market perception. Additionally, the company reported a GAAP EPS of -$0.23 for Q1 2026, indicating ongoing profitability challenges. While there has been a recent positive price momentum with a 5-day change of +14.58%, the overall year-to-date change is -75.81%, suggesting a long-term downtrend. The main risk is the Nasdaq warning regarding its share price, which could lead to delisting if not addressed. Therefore, while there are short-term gains, the long-term outlook remains uncertain and warrants caution.
Bewertungskennzahlen
The current forward P/E ratio for Collplant Biotechnologies Ltd (CLGN) is 80.00, compared to its 5-year average forward P/E of 15.56.
Alphio AI Price Scenarios for CLGN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.506-30PRnewswireCollPlant Secures Private Placement Agreement for $2.6 Million
9.505-29seekingalphaCollPlant Reports Q1 Earnings Results
9.505-29PRnewswireCollPlant Reports Q1 2026 Financial Results and Corporate Update
9.505-29NewsfilterCollPlant Reports Q1 2026 Financial Results and Strategic Developments
- 7.504-13PRnewswire
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead
CLGN FAQ — answered by Alphio AI
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen). It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).
Collplant Biotechnologies Ltd is not a strong buy at the moment. The current price is $0.358, which is significantly below the $1 compliance threshold set by Nasdaq, raising concerns about its market perception. Additionally, the company reported a GAAP EPS of -$0.23 for Q1 2026, indicating ongoing profitability challenges. While there has been a recent positive price momentum with a 5-day change of +14.58%, the overall year-to-date change is -75.81%, suggesting a long-term downtrend. The main risk is the Nasdaq warning regarding its share price, which could lead to delisting if not addressed. Therefore, while there are short-term gains, the long-term outlook remains uncertain and warrants caution.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.